Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8771699 | The Journal of Urology | 2018 | 6 Pages |
Abstract
Early prostate specific antigen doubling time less than 9 months, calculated using prostate specific antigen values before and up to biochemical recurrence, is associated with an increased risk of castration resistant prostate cancer, metastases, and prostate cancer specific and all cause mortality among men with biochemical recurrence after radical prostatectomy. Early prostate specific antigen doubling time allows for risk stratification at biochemical recurrence and before prostate specific antigen doubling time is calculable, enabling these men to be referred for early aggressive secondary treatment and/or clinical trials.
Keywords
PSABCRACMPSADTPCSMCRPCProstate specific antigenShared Equal Access Regional Cancer HospitalSEARCHRadical prostatectomyPSA doubling timeCastration resistant prostate cancerNeoplasm recurrenceBiochemical recurrenceLocalProstate cancer specific mortalityProstatic neoplasmsAll cause mortalityprostate-specific antigenProstatectomyprognosis
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Anna E. Teeter, Kagan Griffin, Lauren E. Howard, William J. Aronson, Martha K. Terris, Christopher J. Kane, Christopher L. Amling, Matthew R. Cooperberg, Stephen J. Freedland,